The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
- The first patient has been dosed in the ONKORAS-101 trial for the study of BBO-8520 in adult subjects with KRAS G12C non-small cell lung cancer - BBO-8520 is a first-in-class orally bioavailable and ...
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) released new clinical data for its KRAS G12C inhibitor BBO-8520, according to a company press release, showing response rates in non-small cell lung ...
BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRAS G12C inhibitor-experienced NSCLC patients BBO-8520 monotherapy continues to show highly ...
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results